The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

Inclusion Criteria: * Male or female participant \>= 20 years old. * Participant has Type 2 Diabetes Mellitus and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the Screening Phase * Participant has been receiving a stable dose (i.e., same type and regimen) of ACEi and/or ARB for at least three months prior to the Screening Phase. However, participant may have switched to different brands but at equivalent doses during the three months prior to the Screening Phase. * Participant is not expected to begin dialysis for at least 6 months. * If female, participant is not breast feeding or is not pregnant. * For entry into the Treatment Phase, the participant must satisfy the following criteria based on the Screening laboratory values: * Estimated glomerular filtration rate (GFR) between 15-90 mL/min/1.73m2 by simplified Modification in Diet in Renal Disease (MDRD) formula * Urinary albumin to creatinine ratio (UACR) between 100 and 3000 mg/g as determined by the mean of the three first morning void urine specimens obtained within one week of each other * Corrected serum calcium level \<= 9.8 mg/dL * intact parathyroid hormone (iPTH) value between 35-500 pg/mL * Glycosylated hemoglobin A1c (HbA1c) \<= 12% * Serum albumin \> 3.0 g/dL * Negative urine pregnancy test for female participants Exclusion Criteria: * Participant has previously been on prescription-based vitamin D therapy within the six months prior to the Sc…